Genetics of serum lipoprotein disorders;Genski poremećaji serumskih lipoproteina

Paediatria Croatica

Volumn 49, Issue 3, 2005, Pages 133-139

  Reiner, Željko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Dyslipidemias genetics, complications, therapy; Hyperlipidemia genetics, complications, therapy; Hypertriglyceridemia genetics, complications, therapy

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN C2; CHOLESTEROL; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SITOSTEROL;

ABETALIPOPROTEINEMIA; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETICS; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; HYPOBETALIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PANCREATITIS; REVIEW; SMITH LEMLI OPITZ SYNDROME; SYSTEMATIC REVIEW; TANGIER DISEASE;

EID: 27544438206     PISSN: 13301403     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. U: Scriver CR, Beaudet AL, Sly WS, Valle D. The Metabolic and Molecular Basis of Inherited Disease. 8 izd., New York, McGraw-Hill; 2001. str. 2863-913.
2. Sudhof TC, Goldstein JL, Brown MS, Russel DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science 1985;228:815-22.
3. Heath KE, Gahan M, Whittall RA, Humphries SE. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis 2001;154:243-6.
4. Muller PY, Miserez AR. Large heterogeneity of mutations in the gene encoding the low-density lipoprotein receptor in subjects with familial hypercholesterolaemia. Atherosclerosis 2004;(Suppl 5):1-5.
5. Varret M, Rabes JP, Saint JB, Cenaro A, Marinoni JC, Civeira F. A third major locus for autosomal dominant hypercholesterolaemia maps to 1p34.1-p32. Am J Med Genet 1999;64:1378-87.
6. Hunt SC, Hopkins PN, Bulka K, McDermott MT, Thorne TL, Wardell BB. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol 2000;20:1089-93.
7. Area M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002;359:841-7.
8. Williams RR, Hunt SC, Schumacher C, Hegele RA, Leppert MF, Ludwig EH. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6.
9. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6.
10. WHO-Human Genetics Program. Division of Noncommunicable Diseases. Familial Hypercholesterolemia - Report of a second WHO Consultation, WHO, Geneva, 1999.
11. Heath KE, Humphries SE, Middelton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH). Eur J Hum Gen 2001;9:244-52.
12. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1999;143:41-54.
13. ten Asbroek AHA, Marang-van de Mheen PJ, Defesche JC, Kastelein JJP, Gunning-Schepers LJ. Results from a family and DNA based active identification programme for familial hypercholesterolaemia. J Epidemiol Community Health 2001;55:500-2.
14. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. A cost-effectiveness analysis of different approaches to screening for familial hypercholesterolaemia. BMJ 2002;324:1303-6.
15. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, Scheerder RLJM, Kastelein JJP. Review of first 5 years of screening for familial hypecholesterolaemia in The Netherlands. Lancet 2001;357:165-8.
16. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol 2003;23:335-8.
17. Kwiterovich PO Jr. Identification and treatment of heterozygous familial hypercholesterolemia in children and adolescents. Am J Cardiol 1993;72:30D-70D.
18. Ose L, Tonstad S. The detection and management of dyslipidaemia in children and adolescents. Acta Paediatr 1995;84:1213-5.
19. Dumić M , Špehar Uroić A, Francetić I, Puretić Z, Matišić D, Kes P, Reiner Ž. Trogodišnji dječak - homozigot za autosomno dominantnu familijarnu hiperkolestrolemiju. Lij Vjesn 2005;(Supl 3):79.
20. Hennermann JB, Herwig J, Marz W, Asskali F, Bohles HJ. Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Eur J Pediatr 1998;157:912-8.
21. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozigous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-12.
22. Stein EA, Illingworth DR, Kwiterovich PO, Jr, Liacouras CA, Siimes MA, Jacobson MS. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999;281:137-44.
23. Smilde TJ, van Wissen S, Wollerheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
24. Reiner Ž. Statini u primarnoj i sekundarnoj prevenciji koronarne bolesti, Medicus 2003;12:85-90.
25. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of Ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolaemia. Circulation 2002;105:2469-75.
26. Thompson GR, Mahler VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
27. Park JW, Merz M, Braun P. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolaemia. Atherosclerosis 1998;139:401-9.
28. Kes P, Reiner Z. Extracorporeal treatment for refractory hyperlipidemia. Acta Med Croatica 1999;53:83-92.
29. Stangl MJ, Beuers U, Schauer R, Lang T, Gerbes A, Briegel J. Die allogene Lebertransplantation - eine Form der "Gentherapie" bei metabolishen Erkrankungen. Muenchener Ergebnisse und Uebersicht. Chirurg 2000;71:808-19.
30. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller DW. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994;6:335-41.
31. Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ, III. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-54.
32. Tybjaerg-Hansen A, Humphries S. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolaemia and premature coronary artery disease. Atherosclerosis 1992;96:91-107.
33. Hansen PS, Defesche JC, Kastelein JJP. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. Arterioscler Thromb Vasc Biol 1997;17:741-7.
34. Miserez AR, Keller W. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1719-29.
35. Reiner Ž. Promjena načina života - ključni čimbenik u lijecenju hiperlipidemija. Medicus 2000;9:49-58.
36. Genest J. Lipoprotein disorders and cardiovascular risk. J Inherit Metab Dis 2003;26:267-87.
37. Reiner Ž, Salzer B. The effects of omega-3 fatty acids on serum lipoproteins and apoproteins in patients with hyperlipoproteinaemia. Period Biol 1993;95:484.
38. Sing K, Ballantyne CM, Ferlic L. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atheroslerosis, response to therapy, and future clinical events: lipoproteins and coronary atherosclerosis study. Atherosclerosis 1999;144:435-42.
39. Nierman MC, Rip J, Twish J, Meulenberg JJ, Kastelein JJ, Stroes ES, Kuivenhoven JA. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice. Neth J Med 2005;63:14-9.
40. Benlian P, De Gennes JL, Foubert L. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;375:848-54.
41. Connor WE, DeFrancesco C, Connor SL. n-fatty acids from fish oil: Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann NY Acad Sci 1993;683:16-34.
42. Tedeschi-Reiner E, Reiner Ž. Omega-3 masne kiseline u prevenciji kardiovaskularnih bolesti. Medix 2002;8:29-30.
43. Fojo SS, Brewer HB Jr. The familial hyperchylomicronemia syndrome. JAMA 1991;265:904-8.
44. Wilson CJ, Oliva CP, Maggi F, Catapano AL, Calandra S. Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. Ann Neurol 2003;53:807-10.
45. Connelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 1998;35:547-72.
46. Pajukanta P, Nuotio I, Terwilliger JD, Porkka KV, Ylitalo K, Pihlajamaki J. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 1998;18:369-73.
47. Aouizerat BE, Allayee H, Cantor RM, Davis RC. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Human Genet 1999;65:397-412.
48. Choon H, Xin Y, Hopkins PN, Cawthon RM, Hasstedt SJ, Hunt SC. Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides. Hum Genet 2005;16 (e-objava prije tiskanja)
49. Smelt AH, de Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Sem Vasc Med 2004;4:249-57.
50. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
51. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005;26:355-61.
52. Whitfield AJ, Barrett PH, von Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. Clin Chem 2004;50:1725-32.
53. Di Leo E, Lancellotti S, Penacchioni JY, Cefalu AB, Averna M, Pisciotta L, Bertolini S, Calandra S, Gabelli C, Tarugi P. Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. Atherosclerosis 2005;180:311-8.
54. Stein O, Stein Y. Lipid transfer proteins and atherosclerosis. Atherosclerosis 2005;178:217-30.
55. Soumian S, Albrecht C, Davies AH, Gibbs RG. ABCA1 and atherosclerosis. Vasc Med 2005;10:109-19.
56. Ayyobi AF, McGladdery SH, Chan SJ, Mancini GB, Hill JS, Frohlich J. Lecitin:cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis 2004;177:361-6.
57. Klein HG, Lohse P, Pritchard PH. Two allelic mutations in the lecitin-cholesterol acyltransferase gene associated with the fish eye syndrome. J Clin Invest 1992;89:499-506.
58. Miida T, Zhang B, Obayashi K, Seino U, Zhu U, Ito T, Nakamura Y, Okada M, Saku K. T13M mutation of lecitin-cholesterol.acyltransferase gene causes fish-eye disease. Clin Chim Acta 2004;343:201-8.
59. Calabresi L, Pisciotta L, Constantin A, Frigerio I, Eberini I. The molecular basis of lecitin: cholestrol:acyltransferase deficiency syndromes. A comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arteriocler Thromb Vasc Biol 2005;30 (e-objava prije tiskanja)
60. Mogadashian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 2004;27:42-50.
61. Dotti MT, Lutjohann D, von Bergman K, Federico A. Normalisation of serum cholesterol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDLK apheresis. Neurol Sci 2004;25:185-91.
62. Boldrini R, Devito R, Biselli R, Filocamo M, Bosman C. Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy. Pathol Res Pract 2004;200:231-40.
63. Correa-Cerro LS, Portir FD. 3 beta-hydroxysterol Delta 7-reductase and the Smith-Lemli-Opitz syndrome. Mol Genet Metab 2005;84:112-26.
64. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK. Human cholesterol-7 alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002;110:109-17.
65. Pullinger CR, Kane JP, Malloy MJ. Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. Expert Rev Cardiovasc Ther 2003;1:107-19.
66. Beigueux A, Hofman AF, Young SC. Human CYP7A1 deficiency: progress and enigmas. J Clin Invest 2002;110:29-31.
67. Hovingh GK, Van Wijland MJ, Brownlie A, Bisoendial RJ, Heyden MR, Kastelein JJ, Groen AK. The role of ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. J Lipid Res 2003;44:1251-5.
68. Pisciotta L, Hamilton-Craig I, Tarugi P, Bellocchio A. Familial HDL deficiency due to ABCA1 gene mutation with or without other genetic lipoprotein disorders. Atherosclerosis 2004;172:309-20.
69. Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005;16:139-45.
70. Genest J, Bard J.M., Fruchart JC. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arteroscler Thromb 1993;13:1728-37.
71. Rader DJ, Ikewaki K, Duverger N. Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993;342:1455-8.
72. Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabudri H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004;45:448-55.
73. Nagano M, Yanoshita S, Hirano K, Takano M, Maruyama T. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 2004;11:110-21.
74. Wang J, Joy T, Myamin D, Frohlich J, Hegele RA. Phenotypic heterogeneity of sitosterolemia. J Lipid Res 2004;49:2361-7.